tiprankstipranks
Crinetics Pharma (CRNX)
NASDAQ:CRNX
US Market
CRNX
Crinetics Pharmaceuticals
RESEARCH TOOLSreports
Want to see CRNX full AI Analyst Report?

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

785 Followers
See the Price Targets and Ratings of:

CRNX Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Crinetics
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$88.90
▲(116.83% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $88.90 with a high forecast of $97.00 and a low forecast of $80.00. The average price target represents a 116.83% change from the last price of $41.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","44":"$44","62":"$62","80":"$80","98":"$98"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,44,62,80,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.52,39.32615384615385,44.13230769230769,48.93846153846154,53.744615384615386,58.550769230769234,63.35692307692308,68.16307692307691,72.96923076923076,77.77538461538461,82.58153846153846,87.3876923076923,92.19384615384615,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.52,38.70307692307693,42.886153846153846,47.06923076923077,51.252307692307696,55.43538461538462,59.618461538461546,63.80153846153846,67.98461538461538,72.1676923076923,76.35076923076923,80.53384615384616,84.71692307692308,{"y":88.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.52,38.018461538461544,41.51692307692308,45.01538461538462,48.51384615384616,52.012307692307694,55.510769230769235,59.00923076923077,62.50769230769231,66.00615384615385,69.50461538461539,73.00307692307692,76.50153846153847,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.35,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$97.00Average Price Target$88.90Lowest Price Target$80.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on CRNX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$83
Buy
102.44%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)
H.C. Wainwright Analyst forecast on CRNX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$81
Buy
97.56%
Upside
Reiterated
06/15/26
Crinetics: Advancing Endocrine Pipeline and Strong Clinical Data Support Buy Rating, Price Target Maintained at $81
Morgan Stanley Analyst forecast on CRNX
Maxwell Skor
Morgan Stanley
Morgan Stanley
$87→$80
Buy
95.12%
Upside
Reiterated
06/15/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)
Leerink Partners Analyst forecast on CRNX
Joseph Schwartz
Leerink Partners
Leerink Partners
$95
Buy
131.71%
Upside
Reiterated
06/11/26
Leerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRLLeerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRL
Evercore ISI Analyst forecast on CRNX
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$89→$88
Buy
114.63%
Upside
Assigned
05/15/26
Crinetics price target lowered to $88 from $89 at Evercore ISICrinetics price target lowered to $88 from $89 at Evercore ISI
Oppenheimer Analyst forecast on CRNX
Leland Gershell
Oppenheimer
Oppenheimer
$87→$84
Buy
104.88%
Upside
Reiterated
05/11/26
Crinetics price target lowered to $84 from $87 at OppenheimerCrinetics price target lowered to $84 from $87 at Oppenheimer
LifeSci Capital Analyst forecast on CRNX
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$89
Buy
117.07%
Upside
Assigned
05/09/26
LifeSci Capital Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
TD Cowen Analyst forecast on CRNX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Piper Sandler Analyst forecast on CRNX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$97
Buy
136.59%
Upside
Reiterated
05/08/26
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Citizens JMP Analyst forecast on CRNX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$97→$95
Buy
131.71%
Upside
Reiterated
05/08/26
Crinetics price target lowered to $95 from $97 at CitizensCrinetics price target lowered to $95 from $97 at Citizens
JonesTrading Analyst forecast on CRNX
Catherine Novack
JonesTrading
JonesTrading
$97
Buy
136.59%
Upside
Reiterated
05/08/26
We expect data from the Ph2 portion of BALANCE in pediatric CAH data by YE26. At ENDO (June 13-16) we expect full Ph2 data for atumelnant in CAH, long-term data for Palsonify in acromegaly, and additional data for atumelnant in ACTH- dependent Cushing's Syndrome. CRNX has $1.3B in cash, with runway into 2030. $97 PT.
Goldman Sachs Analyst forecast on CRNX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$67
Buy
63.41%
Upside
Reiterated
03/01/26
Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Cantor Fitzgerald Analyst forecast on CRNX
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
119.51%
Upside
Reiterated
02/26/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Robert W. Baird Analyst forecast on CRNX
Brian Skorney
Robert W. Baird
Robert W. Baird
$58→$62
Buy
51.22%
Upside
Reiterated
09/26/25
Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
J.P. Morgan Analyst forecast on CRNX
Jessica Fye
J.P. Morgan
J.P. Morgan
$53→$52
Buy
26.83%
Upside
Reiterated
09/24/25
Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on CRNX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$83
Buy
102.44%
Upside
Reiterated
06/29/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)
H.C. Wainwright Analyst forecast on CRNX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$81
Buy
97.56%
Upside
Reiterated
06/15/26
Crinetics: Advancing Endocrine Pipeline and Strong Clinical Data Support Buy Rating, Price Target Maintained at $81
Morgan Stanley Analyst forecast on CRNX
Maxwell Skor
Morgan Stanley
Morgan Stanley
$87→$80
Buy
95.12%
Upside
Reiterated
06/15/26
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)
Leerink Partners Analyst forecast on CRNX
Joseph Schwartz
Leerink Partners
Leerink Partners
$95
Buy
131.71%
Upside
Reiterated
06/11/26
Leerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRLLeerink sees favorable readthrough to Crinetics after Camurus' Oclaiz CRL
Evercore ISI Analyst forecast on CRNX
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$89→$88
Buy
114.63%
Upside
Assigned
05/15/26
Crinetics price target lowered to $88 from $89 at Evercore ISICrinetics price target lowered to $88 from $89 at Evercore ISI
Oppenheimer Analyst forecast on CRNX
Leland Gershell
Oppenheimer
Oppenheimer
$87→$84
Buy
104.88%
Upside
Reiterated
05/11/26
Crinetics price target lowered to $84 from $87 at OppenheimerCrinetics price target lowered to $84 from $87 at Oppenheimer
LifeSci Capital Analyst forecast on CRNX
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$89
Buy
117.07%
Upside
Assigned
05/09/26
LifeSci Capital Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
TD Cowen Analyst forecast on CRNX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Piper Sandler Analyst forecast on CRNX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$97
Buy
136.59%
Upside
Reiterated
05/08/26
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Citizens JMP Analyst forecast on CRNX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$97→$95
Buy
131.71%
Upside
Reiterated
05/08/26
Crinetics price target lowered to $95 from $97 at CitizensCrinetics price target lowered to $95 from $97 at Citizens
JonesTrading Analyst forecast on CRNX
Catherine Novack
JonesTrading
JonesTrading
$97
Buy
136.59%
Upside
Reiterated
05/08/26
We expect data from the Ph2 portion of BALANCE in pediatric CAH data by YE26. At ENDO (June 13-16) we expect full Ph2 data for atumelnant in CAH, long-term data for Palsonify in acromegaly, and additional data for atumelnant in ACTH- dependent Cushing's Syndrome. CRNX has $1.3B in cash, with runway into 2030. $97 PT.
Goldman Sachs Analyst forecast on CRNX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$67
Buy
63.41%
Upside
Reiterated
03/01/26
Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Cantor Fitzgerald Analyst forecast on CRNX
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
119.51%
Upside
Reiterated
02/26/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Robert W. Baird Analyst forecast on CRNX
Brian Skorney
Robert W. Baird
Robert W. Baird
$58→$62
Buy
51.22%
Upside
Reiterated
09/26/25
Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
J.P. Morgan Analyst forecast on CRNX
Jessica Fye
J.P. Morgan
J.P. Morgan
$53→$52
Buy
26.83%
Upside
Reiterated
09/24/25
Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

3 Months
Leland GershellOppenheimer
Success Rate
14/16 ratings generated profit
88%
Average Return
+18.04%
Copying Leland Gershell's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +18.04% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
12/20 ratings generated profit
60%
Average Return
+22.96%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +22.96% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
18/31 ratings generated profit
58%
Average Return
+45.56%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 58.06% of your transactions generating a profit, with an average return of +45.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
18
18
10
13
15
Buy
3
3
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
21
11
14
16
In the current month, CRNX has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 88.90.
Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.22 with a range of -$1.35 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CRNX is -$1.22 with a range of -$1.35 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $14.82M with a range of $12.50M to $16.40M. The previous quarter’s sales results were $10.73M. CRNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.
Next quarter’s sales forecast for CRNX is $14.82M with a range of $12.50M to $16.40M. The previous quarter’s sales results were $10.73M. CRNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?
Based on analyst ratings, Crinetics Pharma’s 12-month average price target is 88.90.
    What is CRNX’s upside potential, based on the analysts’ average price target?
    Crinetics Pharma has 116.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRNX a Buy, Sell or Hold?
          Crinetics Pharma has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Crinetics Pharma’s price target?
            The average price target for Crinetics Pharma is 88.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $97.00 ,the lowest forecast is $80.00. The average price target represents 116.83% Increase from the current price of $41.
              What do analysts say about Crinetics Pharma?
              Crinetics Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of CRNX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.